Fair Value Measurements (Tables)

9 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of changes in the Company's goodwill

	Human Health Segment		Pharmaceutical Ingredients Segment			Performance Chemicals Segment			Total Goodwill
Balance as of June 30, 2016	$	66,039	$	1,651		$	181		$	67,871
Citron and Lucid product acquisition		173,907		-			-			173,907
Changes in foreign currency exchange rates		-		(30	)		(7	)		(37	)
Balance as of March 31, 2017	$	239,946	$	1,621		$	174		$	241,741

Schedule of summary of valuation of financial assets and liabilities

	Fair Value Measurements at March 31, 2017 Using
	Quoted Prices in Active  Markets (Level 1)		Significant  Other  Observable  Inputs (Level 2)		Significant  Unobservable  Inputs  (Level 3)		Total
Cash equivalents:
Time deposits		-	$	5,490		-	$	5,490
Investments:
Time deposits		-		1,966		-		1,966
Foreign currency contracts - assets (1)				27				27
Foreign currency contracts - liabilities (2)		-		262		-		262
Derivative liability for interest rate swap (3)				249		-		249
Contingent consideration (4)		-		-	$	2,830		2,830

(1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2017.

(2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2017.

(3) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2017.

(4) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2017.

	Fair Value Measurements at June 30, 2016 Using
	Quoted Prices  in Active  Markets  (Level 1)		Significant  Other Observable  Inputs (Level 2)		Significant  Unobservable Inputs  (Level 3)		Total
Cash equivalents:
Time deposits		-	$	6,249		-	$	6,249
Investments:
Time deposits		-		881		-		881
Foreign currency contracts - assets (5)		-		160		-		160
Foreign currency contracts - liabilities (6)		-		169		-		169
Contingent consideration (7)		-		-	$	132		132

(5) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016.

(6) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2016.

(7) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.